Chronic Pain — 10 May 2013

ZohyrdoBy Pat Anson, Editor

The Food and Drug Administration has notified Zogenix Inc. (NASDAQ: ZGNX) that it won’t reach a final decision on the company’s powerful new painkiller, Zohydro, until this summer.

“To our knowledge this sort of delay is unprecedented,” Roger Hawley, CEO of Zogenix, said during a conference call announcing the company’s first quarter results.

The FDA had already informed Zogenix in late February that it would be unable to reach a decision by a March 1 target date. The agency gave no explanation for the added delay.

Read more at National Pain Report.


About Author

Pat Anson, Editor

Pat is Editor in Chief of American News Report. He is a veteran journalist and a former correspondent and producer for HealthWeek (PBS), Nightly Business Report (PBS) and other nationally syndicated shows. Pat has won numerous journalism awards, including a Golden Mike award for investigative reporting.

(0) Readers Comments

Comments are closed.